دورية أكاديمية
Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
| العنوان: | Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis. |
|---|---|
| المؤلفون: | Truong, Thu Minh, Pathak, Gaurav N., Singal, Amit, Taranto, Viktoriia, Rao, Babar K. |
| المصدر: | Annals of Pharmacotherapy; Apr2024, Vol. 58 Issue 4, p416-427, 12p |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 10600280 |
|---|---|
| DOI: | 10.1177/10600280231153863 |